Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Harmony Biosciences Holdings, Inc.
HRMY
NASDAQ·Healthcare·Biotechnology·Mkt cap $2.1B
$37.03
▲ +2.86%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$25.52 - $40.87
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 12.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- FDA-approved first-in-class treatment for narcolepsy with differentiated mechanism of action
- Specialized focus on rare neurological disorders with limited competitive alternatives
- Established commercial infrastructure and market presence for WAKIX distribution
- Orphan drug designation providing regulatory exclusivity and market protection
Bear Case
1 risk
- Average volatility.
Growth
Moderate growth ahead
Expanding WAKIX market penetration and patient awareness in narcolepsy treatment
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+29.8% over 3m
Quality
Excellent
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying HRMY right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 4, 2026
MAY 7, 2026
Reported EPS of $0.55 vs $0.76 consensus (-27.6% surprise). Revenue of $215.4M vs $220.8M expected (-2.5%).
EPS surprise · last 4Q
0 of 1 beats
Q2 26
-27.6%
Next: May 4, 2026
Revenue trend · last 8Q
—
—
+20%
+19%
+16%
+29%
+21%
+17%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$172.8M
$186.0M
$201.3M
$184.7M
$200.5M
$239.5M
$243.8M
$215.4M
Margins · last 8Q
Gross
—
Operating
—
Profit
15.1%
Wall Street consensus
6 analysts · 33% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
33%
Hold
50%
Sell
17%
Median Price Target
—
Latest: Deutsche Bank · Jun 30, 2026
vs Industry
How HRMY stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related